Daratumumab-based first-line therapy benefit multiple myeloma patients in a real-world setting: a multi-center retrospective propensity score-match study
Key Points
The aim is to assess the impact of daratumumab-based therapy on patient outcomes in multiple myeloma.
Multi-center retrospective analysis
Propensity score matching
Evaluation of depth of response, progression-free survival, and overall survival
Daratumumab therapy improved depth of response
Enhanced progression-free survival (PFS) noted
Overall survival (OS) benefits observed, although not uniform across all patients
Abstract
In real-world settings, daratumumab-based first-line therapy improved the depth of response, PFS, and OS, though not all patients benefited.
Daratumumab-based first-line therapy benefit multiple myeloma patients in a real-world setting: a multi-center retrospective propensity score-match study | Synapse